Loading...
NPI 1386305407 · Bridgeview, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rt Pcr Test Near Me Inc is a clinical medical laboratory provider located in Bridgeview, Illinois. This profile covers 3 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Rt Pcr Test Near Me Inc |
| Address | 7124 W 83rd St Unit D |
| City | Bridgeview |
| State | IL |
| ZIP | 60455 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 2, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $12.7M |
| Medicaid | $4.7M |
RT PCR TEST NEAR ME INC appears to operate as a specialized clinical molecular laboratory focused on respiratory pathogen detection and viral genomic sequencing, driven primarily by codes 87637 and 87913. Medicare billing shows 54.3K claims for 87637 and 20.4K claims for 87913, reflecting heavy throughput on multiplex respiratory NA testing and next‑generation sequencing for SARS‑CoV‑2, while Medicaid volumes mirror that same test mix at scale in-state.
Medicare revenue is highly concentrated: the provider reports $12.7M in total Medicare revenue with its top three Medicare codes accounting for 100.0% of that total. The two dominant Medicare codes are 87637 ($7.6M, 59.6% of Medicare revenue) and 87913 ($5.1M, 40.4% of Medicare revenue), indicating virtually all Medicare receipts come from respiratory pathogen multiplex testing and SARS‑CoV‑2 sequencing services.
Medicaid revenue is likewise narrowly concentrated around the same service lines: total Medicaid revenue is $4.7M and the top three Medicaid codes account for 99.9% of that total. Medicaid is driven by 87913 ($2.5M, 52.7%) and 87637 ($2.2M, 46.4%), with specimen collection and high‑throughput SARS‑CoV‑2 assay codes (G2023, U0003, U0005) contributing only negligible amounts relative to those two codes.
The provider’s payer mix is Medicare‑heavy in scale: lifetime Medicare revenue of $12.7M substantially exceeds lifetime Medicaid revenue of $4.7M, making Medicare the dominant revenue source while Medicaid provides a smaller but still meaningful portion of volume concentrated in the same tests. This asymmetric scale suggests commercial and Medicare contracting will materially shape overall financial performance more than Medicaid.
RT PCR TEST NEAR ME INC is a national standout on the Medicare multiplex respiratory test 87637, where it ranks #4 of 1141 providers and is labeled an "extreme outlier, far above typical national volume for this code." That national rank implies dominant production capacity for multiplex respiratory NA testing relative to peers, while its #2 of 11 rank on Medicare 87913 (90th percentile; described as typical, unremarkable) indicates it is also a significant contributor to SARS‑CoV‑2 sequencing among a small national set of sequencing providers.
Within Illinois Medicaid comparisons the provider shows strong standing for multiplex testing and more modest placement for sequencing. For Medicaid 87637 it ranks #8 of 79 (91th percentile; typical, unremarkable volume) suggesting a strong in‑state position for respiratory NA testing, whereas 87913 ranks #6 of 10 (44th percentile; typical, unremarkable), indicating a more modest role in-state for NGS sequencing.
The NPI was enumerated on 2022-01-02 (≈4 years ago), so this entity has achieved high aggregate volumes and prominent national ranking for at least some codes in a relatively short operational window. Rapid scale to tens of thousands of claims (e.g., 54.3K claims for 87637) since enumeration suggests an intensive, test‑centered business model built quickly after registration.
The near‑complete dependence on a small set of COVID/respiratory codes (Medicare top three = 100.0% of Medicare revenue; Medicaid top three = 99.9% of Medicaid revenue) highlights concentrated service‑line exposure. While that concentration corresponds to clear market leadership on 87637 and meaningful sequencing volume on 87913, it also means revenue will be sensitive to changes in testing demand, clinical guidelines, or reimbursement for those specific codes; ancillary codes such as G2023, U0003, and U0005 contribute only trivial revenue by comparison.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 54,250 | $140 | $7.6M |
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 20,410 | $250 | $5.1M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 20 | $20 | $460 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 3 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 16,520 | $150 | $2.5M |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 16,540 | $130 | $2.2M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,700 | $20 | $39.1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 30 | $70 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 30 | $30 | $680 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 6 | 10 | 16,610 | $150 | $2.9M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 297 | 350 | 400 | $70 | $514.7K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 8 | 80 | 530 | $130 | $505.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 187 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 111 | 400 | 550 | $20 | $90.8K |
Other providers in the same ZIP code as Rt Pcr Test Near Me Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Hussein Latif | IL | General Practice Dentistry | $0 | $10.3M |
| Village Of Bridgeview | IL | Ambulance | $154.4K | $6.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.